The most promising clinical trials in ALS and MS are showing efficacy signals—but SCI is stuck in preclinical promise

The HEALEY ALS Platform Trial and new MS therapies are delivering functional preservation, not just survival extension. Meanwhile, spinal cord injury lacks any Phase II/III trials with positive signals. The gap says something about trial design, not just biology.